“Abemaciclib in real clinical practice of adjuvant therapy of HR+/HER2- high-risk breast cancer: experience of centers in Moscow” (2025) Voprosy onkologii, 71(3), p. OF-2319. doi:10.37469/0507-3758-2025-71-3-OF-2319.